Disease · HP_0002094
Dyspnea
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. Dyspnea. Diseases, record HP_0002094. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0002094
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Dyspnea
- Open Targets ID
- HP_0002094
- Other names
- Abnormal breathing, Breathing difficulty, Difficult to breathe, Difficulty breathing, Dyspnoea, Shortness of breath, Trouble breathing
- Highest stage of its drugs
- Phase 3, for 16 of its 40 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs40
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| FENTANYL | CHEMBL596 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| FUROSEMIDE | CHEMBL35 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| GLYCOPYRRONIUM BROMIDE | CHEMBL1201027 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| NESIRITIDE | CHEMBL1201668 | Protein | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| TIOTROPIUM | CHEMBL1900528 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| TOLVAPTAN | CHEMBL344159 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| BARICITINIB | CHEMBL2105759 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| INDACATEROL MALEATE | CHEMBL1789842 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LIDOCAINE | CHEMBL79 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MECOBALAMIN | CHEMBL2359370 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 40
See all 40 drugsTargets32
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRB2 | Beta-2 adrenergic receptor | 4 | Beta-2 adrenergic receptor agonist | Phase 3 | https://conductscience.org/library/genes/154 | Drugs and targets |
| CHRM3 | Muscarinic acetylcholine receptor M3 | 4 | Muscarinic acetylcholine receptor M3 antagonist | Phase 3 | https://conductscience.org/library/genes/1131 | Drugs and targets |
| CFTR | Cystic fibrosis transmembrane conductance regulator | 3 | Cystic fibrosis transmembrane conductance regulator activator; Cystic fibrosis transmembrane conductance regulator positive modulator | Unknown | https://conductscience.org/library/genes/1080 | Drugs and targets |
| GUCY1A1 | Soluble guanylate cyclase | 3 | Soluble guanylate cyclase activator | Phase 3 | https://conductscience.org/library/genes/2982 | Drugs and targets |
| GUCY1A2 | Soluble guanylate cyclase | 3 | Soluble guanylate cyclase activator | Phase 3 | https://conductscience.org/library/genes/2977 | Drugs and targets |
| GUCY1B1 | Soluble guanylate cyclase | 3 | Soluble guanylate cyclase activator | Phase 3 | https://conductscience.org/library/genes/2983 | Drugs and targets |
| JAK1 | Tyrosine-protein kinase JAK1 | 2 | Tyrosine-protein kinase JAK1 inhibitor | Phase 3 | https://conductscience.org/library/genes/3716 | Drugs and targets |
| JAK2 | Tyrosine-protein kinase JAK2 | 2 | Tyrosine-protein kinase JAK2 inhibitor | Phase 3 | https://conductscience.org/library/genes/3717 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 2 | Glucocorticoid receptor agonist | Phase 2 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| OPRM1 | Mu-type opioid receptor | 2 | Mu opioid receptor agonist | Phase 3 | https://conductscience.org/library/genes/4988 | Drugs and targets |
1 to 10 of 32
See all 32 targetsTrials36
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00475852 | A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure | Phase 3 | 7,141 | 2012-05-10 | Heart Decompensation | NESIRITIDE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01644331 | Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure | Phase 3 | 257 | 2017-04-27 | Heart Failure, Dyspnea | FUROSEMIDE, TOLVAPTAN | Its record names the disease | ClinicalTrials.gov |
| NCT01490125 | The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | 247 | 2013-12-24 | Chronic Obstructive Pulmonary Disease | GLYCOPYRRONIUM BROMIDE, INDACATEROL MALEATE, TIOTROPIUM | Its record names the disease | ClinicalTrials.gov |
| NCT03367156 | Dexamethasone in Controlling Dyspnea in Patients With Cancer | Phase 2 | 135 | 2022-12-21 | Dyspnea, Malignant Neoplasm | DEXAMETHASONE | Its record names the disease | ClinicalTrials.gov |
| NCT01154127 | Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | 108 | 2012-05-07 | Chronic Obstructive Pulmonary Disease | GLYCOPYRRONIUM BROMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01670097 | Dexamethasone Dyspnea Study | Phase 2 | 52 | 2021-02-01 | Advanced Cancers, Hematologic Disorder, Solid Tumors | DEXAMETHASONE | Its record names the disease | ClinicalTrials.gov |
| NCT01491802 | Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPD | Phase 3 | 17 | 2017-08-15 | COPD | UMECLIDINIUM | Its record names the disease | ClinicalTrials.gov |
| NCT06631287 | Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID | Phase 3 | 550 | Long COVID, Sars-CoV-2 Infection, Coronavirus Infections, COVID-19 | BARICITINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT07274696 | Mecobalamin in Promoting Recurrent Laryngeal Nerve Function Recovery After Thyroid Surgery | Phase 3 | 528 | Patients Undergoing Open Thyroid Surgery | MECOBALAMIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00270374 | A Study Comparing Blood Flow and Clinical and Safety Effects of the Addition of Natrecor (Nesiritide), Placebo or Intravenous Nitroglycerin to Standard Care for the Treatment of Worsening Congestive Heart Failure. | Phase 3 | 498 | Symptomatic Decompensated Congestive Heart Failure, Congestive Heart Failure in Acute Coronary Syndrome | NESIRITIDE, NITROGLYCERIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 36
See all 36 trialsComparisons in its trials18
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Nesiritide vs Placebo: Number of Patients With Renal Impairment | 1,032 of 3,498 | 968 of 3,509 | 7,007 | NCT00475852 | Trial comparisons |
| Nesiritide vs Placebo: All-Cause Mortality Through Day 30 | 126 of 3,498 | 141 of 3,509 | 7,007 | NCT00475852 | Trial comparisons |
| Nesiritide vs Placebo: All-Cause Mortality Through Day 180 | 429 of 3,498 | 447 of 3,509 | 7,007 | NCT00475852 | Trial comparisons |
| Nesiritide vs Placebo: serious adverse events | 5 of 3,498 | 2 of 3,509 | 7,007 | NCT00475852 | Trial comparisons |
| Nesiritide vs Placebo: Composite of Persistent or Worsening Heart Failure and All-Cause Mortality | 147 of 3,459 | 165 of 3,462 | 6,921 | NCT00475852 | Trial comparisons |
| Nesiritide vs Placebo: Composite of Cardiovascular Rehospitalization and Cardiovascular Mortality | 372 of 3,423 | 402 of 3,415 | 6,838 | NCT00475852 | Trial comparisons |
| Nesiritide vs Placebo: Composite of Rehospitalization Due to Heart Failure and All-Cause Mortality | 321 of 3,423 | 345 of 3,413 | 6,836 | NCT00475852 | Trial comparisons |
| Tolvaptan vs Placebo: Over-diuresis | 7 of 129 | 3 of 128 | 257 | NCT01644331 | Trial comparisons |
| Tolvaptan vs Placebo: Development of Worsening Renal Function | 50 of 129 | 34 of 128 | 257 | NCT01644331 | Trial comparisons |
| Tolvaptan vs Placebo: Dyspnea Improvement Measured by Likert Scale at 8 and 24 Hours | 20 of 129 | 26 of 128 | 257 | NCT01644331 | Trial comparisons |
1 to 10 of 18
See all 18 comparisons in its trialsPapers from its trials63
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0002094
GET https://conductscience.org/api/diseases/v1/HP_0002094/drugs?page=2